Clinical trial Recruiting at 2 sites Interventional Ages 60 and up

MediDrink Platinum+ with a new fava bean protein and optional PeptiStrong to improve fitness in older adults with sarcopenia

Official title: Prospective, Open-Label, Multicenter Study to Characterise the Effects of Co-administration of MediDrink Platinum+ Formula Containing Novel Protein Blend SPR-01 and Fava Bean Protein Hydrolysate on Fitness in an Aged Population

Run by Nuritas Ltd · NCT07322653 · Data updated 2026-11-12

This trial will see if MediDrink Platinum+ with a novel protein blend, given alone or together with PeptiStrong, improves fitness in malnourished adults aged 60 and older who have sarcopenia.

More Sarcopenia in Elderly trials

Quick facts

Study typeInterventional
Ages60 Years and up
SexAll
Enrollment75 (estimated)
SponsorNuritas Ltd
Industry-sponsored
Locations2 sites (Budapest and 1 other locations)
StatusRecruiting
StartedSeptember 10, 2025
Main results expectedOctober 1, 2026
Study endsJanuary 2, 2027
Registry record updatedJanuary 7, 2026
Trial IDNCT07322653 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are ambulatory adults aged 60 or older who are malnourished (MNA < 11), have sarcopenia (SARC-F ≥ 4), a BMI ≤ 25 kg/m², can eat orally, and can provide informed consent.

Probably not a fit

Patients who cannot eat orally, have acute infection, intestinal obstruction, uncontrolled liver or renal failure, co-morbidities requiring special diets (e.g., uncontrolled diabetes or advanced kidney disease), recent use of certain supplements or metabolic steroids, or known intolerance to the products are unlikely to benefit or are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicentre, randomized active-control study enrolling 75 malnourished, sarcopenic adults aged 60+ using a 'Y' design where everyone starts on the base MediDrink Platinum formula for two weeks and then is randomized to receive the SRP-01 protein blend alone (n=37) or SRP-01 plus PeptiStrong (n=38) for 10 weeks. Dosing is individualized but provides at least 1200 kcal/day from the drink, with PeptiStrong dosed at 2.4 g/day when used. The primary outcome is change in general fitness measured by the Barthel Index, with secondary endpoints including hand-grip strength, the timed up-and-go test, and changes in fat-free body mass. The trial is sponsored by Nuritas Ltd in collaboration with Medifood Hungary and conducted at sites in Hungary.

Why it matters

Potential benefit: If successful, the intervention could improve daily functioning and muscle mass in malnourished older adults with sarcopenia, potentially lowering care needs and frailty.

How similar studies have gone: General protein supplementation has shown modest benefits for muscle mass and function in older adults, but the specific SRP-01 fava-bean blend and the PeptiStrong peptide combination are novel and not yet proven in large trials.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 60 years or older
* BMI ≤ 25 kg/m²
* Malnourished (mini nutritional assessment MNA \<11
* Sarcopenic: SARC-F score ≥ 4
* Capable or oral feeding either alone or assisted
* Ambulatory (WHO PS/ECOG 0-3)
* Ability to complete questionnaires and self assess health status
* Ability to provide consent

Exclusion Criteria:

* Patient cannot eat orally
* Acute Infection
* Proven Intestinal obstruction
* Co-morbidities requiring a special diet (diabetes, kidney disease etc.)
* Liver dysfunction
* Acute or chronic renal failure
* Uncontrollable nausea or vomiting
* Use of megestrol acetate or metabolic steroids
* Dietary supplement use in the last 3 months
* Known intolerance or allergy to the investigational products
* Participation in any clinical trial within the last 3 months

Where it's running

  • Országos Korányi Pulmonológiai Intézet
    Budapest, Hungary
    Recruiting
  • Sóstói Szivárvány Idősek Otthona
    Nyíregyháza, Hungary
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.